Company profile
GALECTIN THERAPEUTICS INC
NASDAQ:GALTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BELAPECTIN | phase2_3 | — | 6 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00388700 | phase2 | withdrawn | 2006-10-01 | 2009-06-01 | Galectin Therapeutics Inc. | A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer |
| NCT02407041 | phase2 | completed | 2015-09-01 | 2018-03-01 | Galectin Therapeutics Inc. | An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis |
| NCT02421094 | phase2 | completed | 2015-09-01 | 2016-09-27 | Galectin Therapeutics Inc. | Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis |
| NCT02462967 | phase2 | completed | 2015-06-01 | 2017-10-01 | Galectin Therapeutics Inc. | Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis |
| NCT00110721 | phase2 | terminated | 2005-05-01 | 2007-06-01 | Galectin Therapeutics Inc. | GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer |
FDA applications (0)
No records yet.